The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis
- 10 November 2012
- journal article
- research article
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 31 (2) , 206-211
Abstract
This study was performed to investigate the effects of the co-administration of proton pump inhibitor (PPI) on the efficacy of bisphosphonate (BP) treatment for osteoporosis. A total of 180 women with low bone mineral density were randomly divided into four groups, one in which sodium risedronate was administered with sodium rabeprazole and one in which only risedronate was administered (BP + PPI and BP groups, respectively). The biomarkers were measured at the baseline and every 3 months, inlcuding: N-terminal telopeptide of type I collagen corrected for creatinine, bone-specific alkaline phosphatase (BAP), parathyroid hormone, bone mineral density (BMD) of the lumbar spine and physical parameters evaluated according to the SF-36v2™ Health Survey. Statistical comparisons of these parameters were performed after 9 months. Data were available for a total of 137 patients (62 in the BP group and 75 in the BP + PPI group). The Δ % value of increase in BMD and improvement of physical functioning in the BP + PPI group were significantly larger, and its decrease in BAP in the BP + PPI group was significantly smaller than that in the BP group. It is expected that risedronate administration in combination with a PPI may be more effective not only for treating osteoporosis but also improving physical fitness than treatment with risedronate alone.Keywords
This publication has 14 references indexed in Scilit:
- Proton Pump Inhibitor Use and the Antifracture Efficacy of AlendronateArchives of internal medicine (1960), 2011
- Effectiveness of Bone Density Measurement for Predicting Osteoporotic Fractures in Clinical PracticeThe Journal of Clinical Endocrinology & Metabolism, 2007
- Multi-Detector Row CT Imaging of Vertebral Microstructure for Evaluation of Fracture RiskJournal of Bone and Mineral Research, 2005
- Upper Gastrointestinal Tract Safety of Risedronate: A Pooled Analysis of 9 Clinical TrialsMayo Clinic Proceedings, 2002
- Upper Gastrointestinal Tract Safety Profile of AlendronateArchives of internal medicine (1960), 2000
- Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal OsteoporosisOsteoporosis International, 2000
- Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal OsteoporosisA Randomized Controlled TrialJAMA, 1999
- Gastrointestinal Absorption of Calcium from Milk and Calcium SaltsNew England Journal of Medicine, 1987
- Diphosphonates: History and mechanisms of actionMetabolic Bone Disease and Related Research, 1981
- The Absorption of Calcium CarbonateAnnals of Internal Medicine, 1967